381. Deputy Lisa Chambers asked the Minister for Health the reason a person (details supplied) cannot qualify under the HSE criteria for the provision of Pembrolizumab to be covered by private health insurance; his plans to afford a discretion in the HSE criteria of 50% tumour expression of PD-L1 in instances in which an oncologist is of the opinion that the treatment is appropriate; if the criterion of 50% tumour expression of PD-L1 will be reconsidered; if an opportunity for a person to qualify under the scheme once a person has started treatment with Pembrolizumab and is shown to be responding to the treatment will be afforded; and if he will make a statement on the matter. [17618/18]

Summary

381. Deputy Lisa Chambers asked the Minister for Health the reason a person (details supplied) cannot qualify under the HSE criteria for the provision of Pembrolizumab to be covered by private health insurance; his plans to afford a discretion in the HSE criteria of 50% tumour expression of PD-L1 in instances in which an oncologist is of the opinion that the treatment is appropriate; if the criterion of 50% tumour expression of PD-L1 will be reconsidered; if an opportunity for a person to qualify under the scheme once a person has started treatment with Pembrolizumab and is shown to be responding to the treatment will be afforded; and if he will make a statement on the matter. [17618/18]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products Reimbursement

  xml · EN · 24 April 2018

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.